Abstract:Objective To systematically review the efficacy and safety of aescinate combined with mannitol in the treatment of cerebral hemorrhage, by the access of meta analysis and on the basis of current clinical research. Methods Retrieved from PubMed, Embase, CNKI, Wanfang database and VIP, randomized controlled trials about therapeutic efficacy of aescinate combined with mannitol in the treatment of cerebral hemorrhage were collected from base-building to Oct.2019. After two reviewers independently screening literature, extracting data and evaluating the quality of included studies, meta-analysis was conducted by using Rev Man5.3. Results A total of 19 RCTs involving 1829 participants were included. Meta analysis showed that the clinical efficacy of aescinate combined with mannitol in the treatment of cerebral hemorrhage was better than that of control group [Rl ^ R=1.27 (95% CI: 1.22, 1.33), P = 0.000); but the risk of adverse reactions was significantly lower than control group [Rl ^ R=0.40 (95% CI: 0.24, 0.65), P = 0.000]; the neurological deficit scores after treatment [WMD=6.98 (95% CI: 6.34, 7.62), P = 0.000] and the absorption of brain edema [WMD=4.38 (95% CI: 3.45, 5.31), P = 0.000] were better than that of control group. Conclusion The current evidence indicates that the aescinate combined with mannitol can significantly promoted the absorption of brain edema,improve the clinical efficacies and neurological deficits, and significantly decreased the risk of adverse reactions. However, due to limited quality of the included studies, it is still necessary to use more foresight, multicenter, large scale well-designed and high quality studies to verify the above conclusion.